Literature DB >> 9264291

Low production of interferon gamma is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals.

H Ullum1, A Cozzi Lepri, K Bendtzen, J Victor, P C Gøtzsche, A N Phillips, P Skinhøj, B Klarlund Pedersen.   

Abstract

A total of 347 HIV-seropositive individuals attending the Department of Infectious Diseases at Rigshospitalet in Copenhagen and 110 age- and sex-matched healthy controls not at risk for HIV infection were included in this study. Interferon gamma (IFN-gamma) production was measured in whole blood of 223 HIV-seropositive individuals (68 had developed AIDS at enrollment) and 99 healthy sex- and age-matched controls 4.5 hr after challenge with phytohemagglutinin. HIV-infected individuals for whom IFN-gamma production was measured were followed with a median follow-up time of 2.89 years (range, 0.02-4.54 years) from the date of enrollment. Survival analysis was performed considering three different end points: (1) a CD4 count below 100 cells/mm3, (2) an AIDS diagnosis defined according to the 1993 Centers for Disease Control definition, and (3) death. The production of IFN-gamma was highly increased in the blood of HIV-infected individuals without AIDS, but decreased in the blood of AIDS patients (both compared to controls). In the HIV-infected individuals, the total production of IFN-gamma was positively correlated with the number of CD8+ T lymphocytes and with the number of CD16+/CD56+ natural killer cells and negatively correlated with serum levels of beta2-microglobulin. Low levels of IFN-gamma production were associated with an increased risk of experiencing a CD4 count below 100 cells/m3 and death, analyzed in both univariate analysis and in multivariate analysis adjusting for CD4 counts and age. Thus, changes in production of IFN-gamma seem to be truly related to the risk for disease progression in HIV infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9264291     DOI: 10.1089/aid.1997.13.1039

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

1.  A T2 cytokine environment may not limit T1 responses in human immunodeficiency virus patients with a favourable response to antiretroviral therapy.

Authors:  Patricia Price; Niamh M Keane; Silvia Lee; Andrew F Y Lim; Elizabeth J McKinnon; Martyn A French
Journal:  Immunology       Date:  2006-06-22       Impact factor: 7.397

2.  Decreased CD40 ligand induction in CD4 T cells and dysregulated IL-12 production during HIV infection.

Authors:  G Vanham; L Penne; J Devalck; L Kestens; R Colebunders; E Bosmans; K Thielemans; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

3.  Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression.

Authors:  Lindi Roberts; Jo-Ann S Passmore; Carolyn Williamson; Francesca Little; Lisa M Bebell; Koleka Mlisana; Wendy A Burgers; Francois van Loggerenberg; Gerhard Walzl; Joel F Djoba Siawaya; Quarraisha Abdool Karim; Salim S Abdool Karim
Journal:  AIDS       Date:  2010-03-27       Impact factor: 4.177

4.  T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB).

Authors:  T Hertoghe; A Wajja; L Ntambi; A Okwera; M A Aziz; C Hirsch; J Johnson; Z Toossi; R Mugerwa; P Mugyenyi; R Colebunders; J Ellner; G Vanham
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

5.  Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection.

Authors:  E Stylianou; P Aukrust; K Bendtzen; F Müller; S S Frøland
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

6.  HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.

Authors:  Brinda Emu; Elizabeth Sinclair; Hiroyu Hatano; April Ferre; Barbara Shacklett; Jeffrey N Martin; J M McCune; Steven G Deeks
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

7.  On-chip structure-switching aptamer-modified magnetic nanobeads for the continuous monitoring of interferon-gamma ex vivo.

Authors:  Guozhen Liu; Chaomin Cao; Shengnan Ni; Shilun Feng; Hui Wei
Journal:  Microsyst Nanoeng       Date:  2019-08-26       Impact factor: 7.127

8.  Drug-induced reactivation of apoptosis abrogates HIV-1 infection.

Authors:  Hartmut M Hanauske-Abel; Deepti Saxena; Paul E Palumbo; Axel-Rainer Hanauske; Augusto D Luchessi; Tavane D Cambiaghi; Mainul Hoque; Michael Spino; Darlene D'Alliessi Gandolfi; Debra S Heller; Sukhwinder Singh; Myung Hee Park; Bernadette M Cracchiolo; Fernando Tricta; John Connelly; Anthony M Popowicz; Richard A Cone; Bart Holland; Tsafi Pe'ery; Michael B Mathews
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.